Ribbon Bio Appoints Jeff Fitzgerald as Vice President, Global Head of Sales to Drive Commercial Growth and Strategic Expansion
'We're thrilled to welcome Jeff to the Ribbon Bio leadership team at this important time, as we commence our exciting first product launch with MiroSynth™ DNA Molecules,' said Jodi Barrientos, CEO.
Reporting directly to Jodi Barrientos, Ribbon's CEO, Mr. Fitzgerald will oversee all aspects of global sales strategy, business development, and market expansion as the company commercializes its technology to produce pristine synthetic DNA molecules to serve advanced applications in biopharma and life sciences.
'We're thrilled to welcome Jeff to the Ribbon Bio leadership team at this important time, as we commence our exciting first product launch with MiroSynth™ DNA Molecules,' said Ms. Barrientos. 'His deep industry experience and customer-first approach make him the ideal leader to help drive our commercial strategy forward, especially as global demand for more complex and highly accurate synthetic DNA continues to rise.'
Mr. Fitzgerald brings more than a decade of successful commercial leadership experience in life science companies, including executive roles at ArcherDx (acquired by Integrated DNA Technologies (IDT)), and IQVIA (formerly Quintiles), where he led high-performing teams, delivered sustained revenue growth across multiple geographies, and supported commercial integrations post-merger and acquisition. His expertise in product launches, building strategic partnerships and scaling go-to-market operations aligns well with Ribbon Bio's mission to redefine what's possible in synthetic biology through precision-engineered DNA.
'I'm very excited to join Ribbon Bio at such a transformative moment,' said Mr. Fitzgerald. 'The company's ability to deliver highly complex and accurate synthetic DNA is unmatched—and I'm looking forward to supporting our partners to bring their most ambitious biological designs to life with MiroSynth™ DNA Molecules.'
MiroSynth™ DNA is built on Ribbon's proprietary algorithm-driven technology and precision enzymatic assembly process, delivering exceptional accuracy and performance for applications initially in biopharma, life sciences, and academic research. Customers and partners across the US, EU, UK, and Australia can now access MiroSynth™ DNA to accelerate their most ambitious scientific work.
This strategic hire follows a year of significant momentum for Ribbon Bio, including key leadership additions, major partnerships in biopharma and life sciences, demonstrated technical advances in its core platform, and growing global demand for synthetic DNA at the highest levels of complexity and precision.
About Ribbon Bio
Ribbon Bio is a synthetic biology leader driving DNA synthesis beyond the limits of current technologies: making the impossible possible. We are redefining scientific possibility with our algorithm-driven technology that produces pristine synthetic DNA molecules, at a high level of accuracy and unprecedented speed, enabling our partners to deliver a new generation of transformative solutions for the health of people and the planet. For more information, visit us at www.ribbonbio.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
29 minutes ago
- Business Wire
Molecular Instruments® Continues RNA Imaging Leadership with Next-Generation miRNA/siRNA Detection and Clinical-Grade Ready-to-Use Kits
LOS ANGELES--(BUSINESS WIRE)--Molecular Instruments® (MI), the inventor of the HCR™ platform, today announced key enhancements to its HCR™ Gold and HCR™ Pro product lines. These upgrades include next-generation chemistry for high-specificity detection of small RNA targets—including microRNAs (miRNAs) and small interfering RNAs (siRNAs)—and the introduction of a new ready-to-use, prefilled dispenser format for automated assay workflows. 'With small RNA detection and ready-to-use dispensers, HCR™ Pro and HCR™ Gold are setting a new standard for clinical-grade workflows." Share Together, these advances represent a pivotal development in delivering clinical-grade RNA imaging performance with seamless, high-throughput usability. Next-Generation HiFi Chemistry Unlocks Small RNA Detection Both HCR™ Gold and HCR™ Pro now incorporate next-generation HCR™ HiFi architecture, enabling robust detection of small RNAs such as miRNA and siRNA with built-in automatic background suppression, allowing for unmatched signal-to-background performance. Researchers can now visualize and quantify low-abundance, short-length targets with the same confidence as typical transcripts—driving new biological insights across both foundational research and translational discovery. Prefilled Dispensers Support Scalable, Clinical-Grade Performance Additionally, MI has begun shipping HCR™ Pro kits in a fully prefilled dispenser format for the DISCOVERY ULTRA automated research platform. This ready-to-use packaging eliminates manual reagent preparation, streamlining setup and minimizing variability between users and runs. By simplifying the workflow and enhancing reproducibility, these prefilled kits mark a critical milestone on the path toward scalable, clinical-grade molecular imaging. 'These upgrades are a major step forward in our vision to make high-performance bioimaging effortless and with the highest levels of precision,' said Dr. Aneesh Acharya, Chief Commercial Officer at Molecular Instruments. 'With small RNA detection and ready-to-use dispensers, HCR™ Pro and HCR™ Gold are setting a new standard for clinical-grade workflows.' The prefilled format is now available for an initial automation platform, with broader compatibility in development. To learn more or place an order, visit About Molecular Instruments Molecular Instruments® ( is a company powering the future of bioimaging through the development of clinical-grade molecular detection technologies. The company offers automated and manual chromogenic and fluorescent in situ hybridization (ISH) assays that seamlessly integrate with existing immunohistochemistry (IHC) and immunofluorescence (IF) workflows. With thousands of users globally, MI is establishing the field standard for RNA detection and supporting applications from academic research to drug development and diagnostics.
Business Wire
29 minutes ago
- Business Wire
i3 Verticals Announces Earnings Release and Conference Call Date for Third Quarter of Fiscal 2025
NASHVILLE, Tenn.--(BUSINESS WIRE)--i3 Verticals, Inc. (Nasdaq: IIIV) ('i3 Verticals' or the 'Company'), announced today that it will release its financial results for the third quarter ended June 30, 2025, on Thursday, August 7, 2025, after the Nasdaq market close. The Company will also host a conference call on Friday, August 8, 2025, at 8:30 a.m. EDT to discuss financial results and operations. To listen to the call live via telephone, participants should dial (844) 887-9399 approximately 10 minutes prior to the start of the call. A telephonic replay will be available from 11:30 a.m. EDT on August 8, 2025, through August 15, 2025, by dialing (877) 344-7529 and entering Confirmation Code 4426770. To listen to the call live via webcast, participants should visit the 'Investors' section of the Company's website, and go to the 'Events & Presentations' page approximately 10 minutes prior to the start of the call. The online replay will be available on this page of the Company's website beginning shortly after the conclusion of the call and will remain available for 30 days. About i3 Verticals The Company provides innovative software and services solutions to its public sector customers. These comprehensive solutions cover a broad range of applications, including cloud native enterprise software, all of which enable state and local governments and related agencies to serve their constituents in an efficient and seamless manner. With thousands of software installations across all 50 states and Canada, i3 Verticals is a leader in the public sector vertical. More information about the Company can be found at
Yahoo
an hour ago
- Yahoo
AM Best Upgrades Credit Ratings of Lincoln Heritage Life Insurance Company
OLDWICK, N.J., July 24, 2025--(BUSINESS WIRE)--AM Best has upgraded the Financial Strength Rating to A (Excellent) from A- (Excellent) and the Long-Term Issuer Credit Rating to "a" (Excellent) from "a-" (Excellent) of Lincoln Heritage Life Insurance Company (Lincoln Heritage) (Springfield, IL). The outlook of these Credit Ratings (ratings) has been revised to stable from positive. The ratings reflect Lincoln Heritage's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, limited business profile and appropriate enterprise risk management. The upgrading of the ratings for Lincoln Heritage reflects a trend of strong and consistent operating performance, with three consecutive years of record operating, underwriting, and investment earnings. The company's strong operating performance is further evidenced in the return on equity ratios, which exceed 20% on a one-, three- and five-year basis. This trend of improved operating performance began in 2022, when the company reported strong underwriting gains mainly driven by a significant decline in death claims. This trend of underwriting income continued through 2024, and continues through first-quarter 2025, as claims trends have moderated over time post the COVID-19 pandemic. Investment income has also increased significantly in recent years, largely driven by growth in invested assets and an improvement in investment yield from the investment portfolio. Lincoln Heritage's strong operating results have been accretive to the balance sheet, with risk-adjusted capital and liquidity metrics improving as its capital has accumulated over the long term. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments. AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED. View source version on
